查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585816

乳癌治疗药物市场：按类型、分销管道划分 - 全球预测 2025-2030 年

Breast Cancer Drugs Market by Type (Anti-Metabolites, Aromatase Inhibitor, CDK 4/6 Inhibitor), Distribution Channel (Ambulatory Surgical Centres, Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年乳癌治疗市值为217.9亿美元，预计到2024年将达到239.4亿美元，复合年增长率为9.96%，到2030年将达到423.7亿美元。

乳癌药物市场包括专门用于治疗和管理乳癌的药物，例如荷尔蒙疗法、化疗、标靶治疗和免疫治疗。该市场是由全球乳癌发病率不断上升推动的，因此需要先进的治疗方法。它们的主要用途是医疗保健系统、医院和专门的癌症治疗中心，这些疗法在早期和晚期癌症管理中发挥重要作用。最终用途范围从个别患者护理到旨在改善癌症结果和生存的公共卫生努力。关键的市场成长要素包括生物技术和个人化医疗的进步，以及对标靶治疗和免疫疗法的接受度不断提高。此外，製药公司之间在研发方面的策略联盟以及强大的法律规范为新参与企业和现有企业创造了获得市场占有率的潜在机会。然而，挑战仍然存在，包括高昂的治疗成本、严格的监管核准以及与癌症治疗相关的副作用。此外，低收入地区也存在一些限制因素，例如在获得先进癌症治疗方面存在差异。为了克服这些挑战，潜在的创新领域包括开发生物相似药以降低成本、增强标靶递送机制，例如基于奈米颗粒的递送系统、基因标记和分析，这包括公司对精准医学的关注。投资临床试验来探索新的药物组合併利用人工智慧推进药物发现过程也可以加速业务成长。市场仍然高度竞争和充满活力，其特点是不断创新和策略伙伴关係关係。公司必须优先考虑以患者为中心的方法，并促进与研究机构和医疗保健提供者的合作，以扩大产品平臺并改善治疗结果，从而应对这种情况。

主要市场统计
基准年[2023] 217.9亿美元
预测年份 [2024] 239.4亿美元
预测年份 [2030] 423.7亿美元
复合年增长率（%） 9.96%

市场动态：揭示快速发展的乳癌药物市场的关键市场洞察

供需的动态交互作用正在改变乳癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 乳癌盛行率增加，女性人口老化加剧
    • 药物技术的进步与研究的改进
    • 政府加强宣传乳癌意识的措施和计划
  • 市场限制因素
    • 乳癌治疗药物的副作用
  • 市场机会
    • 加强製药公司之间的合作与伙伴关係
    • 乳癌治疗新药介绍
  • 市场挑战
    • 药品生产流程的严格规定

波特五力：驾驭乳癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对乳癌药物市场的影响

外部宏观环境因素在塑造乳癌治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解乳癌治疗药物市场的竞争状况

对乳癌治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

乳癌治疗市场中的 FPNV 定位矩阵供应商绩效评估

FPNV定位矩阵是评估乳癌治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘乳癌治疗市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对乳癌治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 乳癌发生率增加和女性人口老化
      • 製药技术的进步与研究的改进
      • 增加政府措施和计划以提高人们对乳癌的认识
    • 抑制因素
      • 使用乳癌药物的不良反应
    • 机会
      • 加强药品製造公司之间的合作与联盟
      • 小说介绍乳癌治疗药物
    • 任务
      • 药品生产流程的严格规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章乳癌治疗药物市场：按类型

  • 代谢抑制剂
  • Aromatase抑制剂
  • CDK 4/6抑制剂
  • HER2抑制剂
  • 荷尔蒙受体
  • 有丝分裂抑制剂

第七章乳癌治疗药物市场：按分销管道

  • 门诊手术中心
  • 诊所
  • 医院
  • 线上管道
  • 零售药房

第八章北美和南美乳癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区乳癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的乳癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • A. Menarini Industrie Farmaceutiche Riunite srl
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05264

The Breast Cancer Drugs Market was valued at USD 21.79 billion in 2023, expected to reach USD 23.94 billion in 2024, and is projected to grow at a CAGR of 9.96%, to USD 42.37 billion by 2030.

In the breast cancer drugs market, the scope encompasses a range of pharmaceuticals specifically designed for the treatment and management of breast cancer, including hormone therapy, chemotherapy, targeted therapy, and immunotherapy. This market is driven by a growing prevalence of breast cancer worldwide, necessitating advanced therapeutics. The application predominantly lies in healthcare systems, hospitals, and specialized cancer treatment centers, where these drugs play a critical role in both early and late-stage cancer management. The end-use scope varies from individual patient care to public health initiatives aimed at improving cancer outcomes and survival rates. Significant market growth factors include advancements in biotechnology and personalized medicine, increasing the acceptance of targeted therapies and immunotherapy. Moreover, strategic collaboration among pharmaceutical companies for R&D efforts and robust regulatory frameworks are creating potential opportunities for new entrants and existing firms to gain market share. However, challenges persist, such as high treatment costs, stringent regulatory approvals, and adverse side effects associated with cancer therapies. Further limitations involve disparities in access to advanced cancer treatments in low-income regions. To overcome these challenges, potential areas for innovation include the development of biosimilars to reduce costs, enhancing targeted delivery mechanisms like nanoparticle-based delivery systems, and focusing on precision medicine through genetic markers and profiling. Business growth could be accelerated by investing in clinical trials that explore new drug combinations and leveraging artificial intelligence to advance drug discovery processes. The nature of the market remains highly competitive and dynamic, characterized by continuous innovations and strategic partnerships. Companies must navigate this landscape by prioritizing patient-centric approaches and fostering collaborations with research institutions and healthcare providers to expand their product pipelines and improve therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 21.79 billion
Estimated Year [2024] USD 23.94 billion
Forecast Year [2030] USD 42.37 billion
CAGR (%) 9.96%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Drugs Market

The Breast Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of breast cancer and rising geriatric population of women
    • Improved advancements and research in drug technologies
    • Growth in government initiatives and programs to spread awareness about breast cancer
  • Market Restraints
    • Adverse effects caused by the use of breast cancer drugs
  • Market Opportunities
    • Increasingly collaboration and partnership among drug manufacturing companies
    • Introduction of novel breast cancer drugs
  • Market Challenges
    • Stringent regulation on drug manufacturing process

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Drugs Market

A detailed market share analysis in the Breast Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Drugs Market

A strategic analysis of the Breast Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Industrie Farmaceutiche Riunite s.r.l., Amgen Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Anti-Metabolites, Aromatase Inhibitor, CDK 4/6 Inhibitor, HER2 Inhibitor, Hormonal Receptor, and Mitotic Inhibitor.
  • Based on Distribution Channel, market is studied across Ambulatory Surgical Centres, Clinics, Hospitals, Online Channels, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of breast cancer and rising geriatric population of women
      • 5.1.1.2. Improved advancements and research in drug technologies
      • 5.1.1.3. Growth in government initiatives and programs to spread awareness about breast cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects caused by the use of breast cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasingly collaboration and partnership among drug manufacturing companies
      • 5.1.3.2. Introduction of novel breast cancer drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulation on drug manufacturing process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Anti-Metabolites
  • 6.3. Aromatase Inhibitor
  • 6.4. CDK 4/6 Inhibitor
  • 6.5. HER2 Inhibitor
  • 6.6. Hormonal Receptor
  • 6.7. Mitotic Inhibitor

7. Breast Cancer Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centres
  • 7.3. Clinics
  • 7.4. Hospitals
  • 7.5. Online Channels
  • 7.6. Retail Pharmacies

8. Americas Breast Cancer Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Breast Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. A. Menarini Industrie Farmaceutiche Riunite s.r.l.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bristol Myers Squibb Company
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Fresenius SE & Co. KGaA.
  • 8. Gilead Sciences, Inc.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Sanofi S.A.
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BREAST CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BREAST CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. BREAST CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 107. BREAST CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023